Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug 27;18(8):2019-2026.
doi: 10.22034/APJCP.2017.18.8.2019.

Current Trends in Management of Oral Mucositis in Cancer Treatment

Abhishek Shankar  1 , Shubham Roy, Menal Bhandari, G K Rath, Aalekhya Sharma Biswas, Ravi Kanodia, Narayan Adhikari, Rashika Sachan
Affiliations

Current Trends in Management of Oral Mucositis in Cancer Treatment

Abhishek Shankar et al. Asian Pac J Cancer Prev. .

Abstract

Oral Mucositis (OM) is among the most common and dreaded toxicities of cancer therapy. It occurs in almost all patients who receive radiation therapy in which areas of oral and oropharyngeal mucosa are included in the treatment field. With the advent of chemotherapy in 1940 and its extended clinical legacy, it is only within the past two decade or so that mucositis’ complex pathobiology has become fully appreciated. There are still many unanswered questions about the risk factors for developing OM, but historically, risk factors have been attributed to both therapy and patient m characteristics. One thing that has been consistent from the initial descriptions of its clinical manifestations has been the frustration on the part of clinicians and patients with the scarcity of therapeutic options to prevent or treat the condition, or effectively ameliorate the symptoms. Clinicians, researchers and those involved in oral and periodontal medicine should join hand in hand in persuit of understanding and developing treatment strategies for treatment of inflammatory conditions like OM in oncology. This will lead to development of effective treatments and reducing the burden of OM and other inflammatory conditions in oncology.

Keywords: Oral Mucositis; cancer; treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Signalling Pathway of Mucositis
See this image and copyright information in PMC

References

    1. Al-Azri AR, Gibson RJ, Keefe DM, Logan RM. Matrix metalloproteinases: do they play a role in mucosal pathology of the oral cavity? Oral Dis. 2013;19:347–59. - PubMed
    1. Al-Dasooqi N, Gibson RJ, Bowen JM, et al. Matrixmetalloproteinases are possiblemediators for the development of alimentary tract mucositis in the dark agouti rat. Exp Biol Med (Maywood, NJ) 2010;235:1244–56. - PubMed
    1. Andreassen C. The biological basis for differences in normal tissue response to radiation therapy and strategies to establish predictive assays for individual complication risk. In: Keefe STSaDM., editor. Pathobiology of Cancer Regimen-Related Toxicities. New York, USA: Springer; 2013. pp. 19–33.
    1. Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol. 2003;39:91–100. - PubMed
    1. Bensinger W, Schubert M, Ang KK, et al. NCCN Task Force Report prevention and management of mucositis in cancer care. J Natl Comp Cancer Netw. 2008;121:2–4. - PubMed